Summit Therapeutics (SMMT) just unveiled an update.
Ujwala Mahatme will step down from Summit Therapeutics Inc.’s Board of Directors on June 12, 2024, due to her growing commitments elsewhere, leaving her positions on the Nominating and Corporate Governance Committee, Compensation Committee, and Audit Committee without any disputes with the company. In the subsequent Annual Meeting, stockholders approved the election of eight directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor for the next fiscal year, and a non-binding vote on executive compensation, with all matters passing as recommended by the Board.
See more insights into SMMT stock on TipRanks’ Stock Analysis page.
